Boehringer Ingelheim: Pulmonary Disease, Chronic Obstructive trials

The registry lists 236 Pulmonary Disease, Chronic Obstructive studies with Boehringer Ingelheim as lead sponsor. 1 are open to participants now and 124 have results posted.

Phase 1 7Phase 2 33Phase 3 81Phase 4 32No phase 83(a study in two phases counts in both)

Studies

Page 1 of 3. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary DiseaseNot yet recruitingNCT07907991Phase 3
• Morbid Rates After Spiriva Chronic Obstructive Pulmonary Disease (COPD) Protocol ChangeCompletedNCT06053541Results posted
• Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in TaiwanCompletedNCT05402020Results posted
• Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) DataCompletedNCT05393245Results posted
• Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative DrugTerminatedNCT05362487Results posted
• A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT05169424Results posted
• A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + VilanterolCompletedNCT05127304Results posted
• Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database StudyCompletedNCT04926233Results posted
• Proof of Concept Study Assessing Technology-Assisted Respiratory Adherence Prototype Version 3 in Individuals With COPDCompletedNCT04795323Phase 2Results posted
• Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in GreeceCompletedNCT04672941Results posted
• Early Intervention Efficacy in COPDCompletedNCT04249310Results posted
• A Study to Test the Combination of Tiotropium and Olodaterol Using the Respimat® Inhaler in People With Chronic Obstructive Pulmonary Disease (COPD) Who Have Different Abilities to InhaleCompletedNCT04223843Phase 4Results posted
• Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple TherapyCompletedNCT04184297Results posted
• A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD)CompletedNCT04172701Results posted
• Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICSCompletedNCT04138758Results posted
• A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT04097223Results posted
• Re-usable Respimat® Soft MistTM Inhaler StudyCompletedNCT04011735Results posted
• A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA TreatmentCompletedNCT04011475Results posted
• A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03979807Results posted
• A Study on Whether Patients Prefer the Spiriva® Respimat® or the Spiriva® Handihaler® for Treating Their Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT03964207Phase 4Results posted
• Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®)CompletedNCT03954132Results posted
• Effectiveness of Triple Therapy in COPDCompletedNCT03724877Results posted
• A Study on the Control of Chronic Obstructive Pulmonary Disease (COPD) in Patients Taking the Combination of Tiotropium and Olodaterol Using the Respimat® InhalerCompletedNCT03663569Results posted
• The OPTI Study in Spain Looks at the History Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Treated With Inhaled Steroids.CompletedNCT03611777Results posted
• Greek NIS Spiolto ELLACTOCompletedNCT03419962Results posted
• Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 AgonistsCompletedNCT03405363Results posted
• Comparative Effectiveness of COPD TreatmentsCompletedNCT03376295Results posted
• Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]CompletedNCT03265145Phase 4Results posted
• The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the DiskusCompletedNCT03240575Phase 4Results posted
• Changes in Health and Functional Status in Patients With Chronic Obstructive Pulmonary Disease During Therapy With Spiolto® Respimat® (AERIAL®)CompletedNCT03165045Results posted
• Cardiovascular Function in COPD PatientsCompletedNCT03055988Phase 4Results posted
• Drug Utilization Study for OlodaterolCompletedNCT03030638Results posted
• Effectiveness and Handling of Spiolto® Respimat ® in COPD Patients - ItalyCompletedNCT03003494Results posted
• Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD PatientsCompletedNCT02969317Phase 1Results posted
• OTIVACTO Spain Non Interventional StudyCompletedNCT02927795Results posted
• Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02864407Results posted
• Effect of Tiotropium + Olodaterol on Breathlessness in COPD PatientsCompletedNCT02853123Phase 4Results posted
• Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT02850978Results posted
• Assessment of Physical Functioning and Handling of Spiolto Respimat in Patients With COPD (OTIVACTO)TerminatedNCT02720757Results posted
• OTIVACTO Regional Center Vienna (RCV) Non-Interventional Study (NIS)CompletedNCT02719639Results posted
• Longitudinal Follow up to Assess Biomarkers Predictive of Emphysema Progression in Patients With COPD (Chronic Obstructive Pulmonary Disease)CompletedNCT02719184Results posted
• SATisfaction and Adherence to COPD TreatmentCompletedNCT02689492Results posted
• Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPDCompletedNCT02683109Phase 4Results posted
• Assessment of Physical Functioning and Handling of Spiolto® Respimat® in Patients With Chronic Obstructive Pulmonary Disease (COPD) Requiring Long-acting Dual Bronchodilation in Routine Clinical PracticeCompletedNCT02675517Results posted
• Safety, Tolerability and Pharmacokinetics and Effect on Inflammation of Oral BI 1026706 in Patients With COPDCompletedNCT02642614Phase 1Results posted
• Comparing the Efficacy of Tiotropium + Olodaterol Fixed Dose Combination (FDC) Over Tiotropium in Improvement of Lung Hyperinflation, Exercise Capacity and Physical Activity in Japanese COPD PatientsCompletedNCT02629965Phase 3Results posted
• Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.CompletedNCT02296138Phase 3Results posted
• Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT02231177Phase 1Results posted
• Changes in Physical Functioning in Patients With COPD During Therapy With a Combination Inhalation TherapyCompletedNCT02173769Results posted
• Combined Bronchodilators in Chronic Obstructive Pulmonary Disease and the Risk of Adverse Cardio-pulmonary EventsCompletedNCT02096731Results posted
• To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of AirwaysCompletedNCT02085161Phase 3Results posted
• Study to Evaluate the Effect on Lung Function and ECG When a Combination of Tiotropium Plus Olodaterol is Administered to Patients With COPD Either From a Single Inhaler or Each Compound is Administered After Each Other From Two Different InhalersCompletedNCT02030535Phase 2Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 2)CompletedNCT02006732Phase 3Results posted
• Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD PatientsCompletedNCT01969721Phase 3Results posted
• Ventilator Adapters for Combivent RespimatTerminatedNCT01969539Phase 4Results posted
• Tiotropium + Olodaterol Fixed Dose Combination (FDC) in Chronic Obstructive Pulmonary Disease (OTEMTO 1)CompletedNCT01964352Phase 3Results posted
• BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic BronchitisCompletedNCT01958008Phase 1Results posted
• Ipratropium Bromide in Peri-Operative COPDCompletedNCT01943552Phase 4Results posted
• Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01937390Results posted
• Preference Tiotropium Respimat Study in COPDCompletedNCT01810692Results posted
• Single Dose Ranging Study of BI 1744 CL (Olodaterol) in Chronic Obstructive Pulmonary DiseaseCompletedNCT01809262Phase 2Results posted
• A Study to Characterize Pharmacokinetics of Tiotropium + Olodaterol Fixed-dose Combination in Japanese Patients With COPD.CompletedNCT01703845Phase 1Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01696058Phase 3Results posted
• Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®CompletedNCT01694771Phase 3Results posted
• Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 1CompletedNCT01663987Phase 4Results posted
• Investigate the Impact of Early Treatment Initiation With Tiotropium in Patients Recovering From Hospitalization for an Acute COPD Exacerbation 2CompletedNCT01662986Phase 4Results posted
• Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) TestCompletedNCT01644734Phase 4Results posted
• Characterization of 24-hour Lung Function Profiles of Inhaled Tiotropium + Olodaterol Fixed Dose Combination in Patients Suffering From Chronic Obstructive Pulmonary DiseaseCompletedNCT01559116Phase 3Results posted
• Japan Long-term Safety for Tiotropium Plus OlodaterolCompletedNCT01536262Phase 3Results posted
• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.CompletedNCT01533935Phase 3Results posted
• Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD PatientsCompletedNCT01533922Phase 3Results posted
• A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPDCompletedNCT01525615Phase 3Results posted
• Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory InfectionCompletedNCT01483625Phase 4Results posted
• Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431287Phase 3Results posted
• Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01431274Phase 3Results posted
• ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical PracticeCompletedNCT01388166Results posted
• SMS Reminder to Assess AdherenceCompletedNCT01308476Results posted
• Tiotropium Respimat Pharmacokinetic Study in COPDCompletedNCT01222533Phase 2Results posted
• Relative Bioavailability of Olodaterol and FluconazoleCompletedNCT01153724Phase 1Results posted
• Relative Bioavailability of of Olodaterol and KetoconazoleCompletedNCT01153711Phase 1Results posted
• Drug Use Survey of RESPIMAT in Patients With COPDCompletedNCT01145053Results posted
• Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary DiseaseCompletedNCT01126437Phase 3Results posted
• Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary DiseaseCompletedNCT01072396Phase 4Results posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry IICompletedNCT01040793Phase 3Results posted
• A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040728Phase 3Results posted
• Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01040689Phase 3Results posted
• Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)CompletedNCT01040403Phase 2Results posted
• Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry ICompletedNCT01040130Phase 3Results posted
• Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an ExampleCompletedNCT01036763Results posted
• Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT01019694Phase 3Results posted
• Spiriva Observational Study Measuring Saint George's Respiratory Questionnaire (SGRQ) in Routine Medical Practice in Central & Eastern European RegionCompletedNCT01006135Results posted
• Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00975195Phase 4Results posted
• Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00932646Phase 3Results posted
• Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary DiseaseCompletedNCT00931385Phase 3Results posted
• Actuation Indicator Trial in Patients With COPDCompletedNCT00928746Phase 3Results posted
• BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPDCompletedNCT00846768Phase 2Results posted
• Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPDCompletedNCT00824382Phase 2Results posted
• Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease IICompletedNCT00796653Phase 3Results posted
• Safety and Efficacy of BI 1744 CL in Patients With Chronic Obstructive Pulmonary Disease ICompletedNCT00793624Phase 3Results posted
• 12 / 48 wk Pivotal PFT vs PBO in COPD IICompletedNCT00782509Phase 3Results posted